APRINOIA Therapeutics: Funding, Investors & Team (Oct 2026)
APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston.
APRINOIA Therapeutics has raised $4.4M across 1 funding round on record, the most recent an undisclosed round of $4.4M announced in Sep 2023.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
APRINOIA Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2023.
APRINOIA Therapeutics Funding Rounds
APRINOIA Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
APRINOIA Therapeutics Funding Compared to Other Biotechnology Startups
APRINOIA Therapeutics' latest round of $4.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like APRINOIA Therapeutics in Biotechnology and Boston
Companies Similar to APRINOIA Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
APRINOIA Therapeutics Funding FAQs
What does APRINOIA Therapeutics do?
APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston.
How much funding has APRINOIA Therapeutics raised?
APRINOIA Therapeutics has raised $4.4M across 1 round on record. The most recent is an undisclosed round of $4.4M announced in Sep 2023.
When did APRINOIA Therapeutics last raise funding?
APRINOIA Therapeutics' most recent funding round on record is an undisclosed round of $4.4M, announced in Sep 2023.
Who is the CEO of APRINOIA Therapeutics?
Ming Kuei Jang is listed as CEO at APRINOIA Therapeutics.
Where is APRINOIA Therapeutics headquartered?
APRINOIA Therapeutics is based in Boston, Massachusetts, United States.
How many employees does APRINOIA Therapeutics have?
APRINOIA Therapeutics is in the 51-100 employee band.
How does APRINOIA Therapeutics' funding compare to other Biotechnology startups?
APRINOIA Therapeutics' latest round of $4.4M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's APRINOIA Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for APRINOIA Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.